GSK fined £37.6m over deals to stifle drug competition
- 8 years ago
GlaxoSmithKline has been fined £37.6 million for striking deals with potential rivals to delay their launch of generic copies of its drug for anxiety disorders and depression. Report by Cordingleyj. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn